SSSushant Suresh

Sushant Suresh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sushant Suresh has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    ARMH3 acts as a central scaffold at the Golgi/TGN through interactions with Arl5, GBF1, and PI4KB

    by Mackenzie K. Scott, Giselle C.T. Klynsoon, Emma E. Walsh, Sushant Suresh, Hunter G. Nyvall, John E. Burke

  • An MR1-specific nanobody capable of blocking MR1T cell activation

    by Timothy A Bates, Corinna A Kulicke, Sintayehu K Gurmessa, Se-Jin Kim, Sushant Suresh, Jules B Reyes-Weinstein, Audrey Hinchliff, John E Burke, David M Lewinsohn, Fikadu G Tafesse

    MR1 is a non-polymorphic, ubiquitously expressed, MHC class I-like antigen-presenting molecule that presents small-molecule metabolites to T cells. Studies have shown that MR1 plays a role in microbial infection, inflammation, and tumor immunity. The antigens it presents include metabolites of microbial and self-origin as well as small-molecule drugs and form stable complexes with MR1 that are displayed on the cell surface to activate T cells. However, unlike classical MHC I and II molecules, the fundamental biology of MR1 remains poorly understood, particularly the mechanisms governing antigen loading and intracellular trafficking. This knowledge gap is largely due to the lack of molecular tools available to precisely manipulate MR1 function. In this study, we describe a high-affinity (1.6 nM KD) anti-MR1 nanobody, MR1Nb1. We characterize the binding of this nanobody including affinity by ELISA and kinetics by BLI. Crucially, we map the binding epitope of MR1Nb1 on MR1 by HDX-MS, providing key insights into the mechanism through which it blocks MR1T cell activation. In functional assays MR1Nb1 effectively and specifically blocks MR1T cell activation by cells infected with M. tuberculosis or treated with M. smegmatis supernatant or the synthetic ligand deazalumazine. MR1Nb1 further stains MR1-ligand complexes on the cell surface in a flow cytometry assay. This nanobody represents a unique and versatile tool for the field, as it can be produced inexpensively and expressed intracellularly within antigen presenting cells. Hence, our study provides a powerful new molecular probe for dissecting the mechanistic underpinnings of MR1 biology and uncover its broader roles in immunity.

  • Open Access

    ARMH3 acts as a central scaffold at the Golgi/TGN through interactions with Arl5, GBF1, and PI4KB

    by Mackenzie K Scott, Giselle Ct Klynsoon, Emma E Walsh, Sushant Suresh, Hunter G Nyvall, John E Burke

    The armadillo repeat protein ARMH3 regulates the activity and localisation of the Golgi resident lipid kinase phosphatidylinositol 4 kinase IIIβ (PI4KB) and the Golgi-specific brefeldin A-resistance guanine nucleotide exchange factor 1 (GBF1) that activates Arf1. ARMH3 localises to the trans Golgi network (TGN) via the GTPase Arl5. We used hydrogen deuterium exchange mass spectrometry (HDX-MS) and AI-enabled modeling to define the interfaces of ARMH3 with its binding partners Arl5, PI4KB, and GBF1. The ARMH3-Arl5 interface was determined to consist of the N and C termini of ARMH3, with Arl5 binding causing conformational changes in ARMH3 located at a shared PI4KB/GBF1 interface. Both PI4KB and GBF1 form mutually exclusive complexes with ARMH3, with GBF1 binding to ARMH3 through a disordered loop we have named the ARMH3 binding region (ABR). The ARMH3 interfaces in PI4KB and GBF1 contain phosphosites, with the phosphomimetic mutation of GBF1 blocking complex formation. These findings provide new insights into the role of ARMH3 as a master coordinator of GTPase and phosphoinositide signaling at the Golgi/TGN.

  • Open Access

    Phosphorylation of the C-terminus of PI4KA inhibits lipid kinase activity

    by Alexandria L Shaw, Sophia Doerr, Hunter G Nyvall, Meredith L Jenkins, Sushant Suresh, Calvin K Yip, Scott D Hansen, John E Burke

    Phosphatidylinositol 4-kinase alpha (PI4KA) is a lipid kinase that generates phosphatidylinositol 4-phosphate (PI4P) from phosphatidylinositol (PI) at the plasma membrane (PM). PI4P generated by PI4KA is essential for both plasma membrane identity and for PIP 2 and PIP 3 signalling driven by the PLC and PI3K family of enzymes. While the structure of PI4KA is known, the regulatory mechanisms that control its activity are undefined. Here, we discovered that PI4KA lipid kinase activity can be inhibited through tyrosine phosphorylation of the kα12 helix of the kinase domain (Y2090). This site can be phosphorylated by multiple tyrosine kinases. Structural studies using cryo-EM and HDX-MS defined the mechanism of how Y2090 phosphorylation inhibits activity, with this being driven through local conformational changes in the kα12 C-terminal helix of the PI4KA kinase domain. PI4KA activity is predominantly controlled through membrane recruitment by EFR3, with phosphorylation inhibiting the EFR3 tethered PI4KA complex. Phosphorylation of the kα12 C-terminal helix is found in multiple PI3Ks and PI4Ks, suggesting this may be an evolutionarily conserved regulatory mechanism for this family of phosphoinositide kinases. Overall, our work reveals novel molecular insight into inhibitory post-translational regulation of PI4KA.

  • Open Access

    Functional NK engagers from OmniClic, a common light-chain platform producing fully human-sequence antibodies in a chicken host species

    by Baisen Zeng, Ingrid Mechin, David Mowrey, Gerry S Rivera, Hunter G Nyvall, Sushant Suresh, John E Burke, William Harriman, Bob Chen, Yasmina Abdiche

    Next-generation antibodies include a growing number of bispecific and multispecific antibodies that are commonly used to redirect the immune system to fight cancer. Herein, we assessed the depth and breadth of epitope coverage as a proxy for functional diversity in human immune repertoires produced by two complementary in vivo platforms utilizing a common light chain, in a chicken (OmniClicTM) or rat (OmniFlic®) host species. We adopted NKp46 as a model to target antigen due to its use in emerging natural killer (NK) immune engagers that are being explored clinically as potentially safer alternatives to traditional CD3-based T cell engagers. To probe the epitope diversity of our antibody repertoires, we performed a detailed high throughput epitope binning study using surface plasmon resonance and corroborated our binning assignments with epitope mapping data deduced from hydrogen deuterium exchange mass spectrometry. Our results revealed broad epitope coverage and nuanced diversity both within and across repertoires, with few epitopes shared, suggesting that the complementary use of OmniClicTM and OmniFlic® produces more comprehensive coverage than either alone. Furthermore, our epitope binning assignments aligned with our complementarity-determining region-based sequence lineage assignments, enabling a direct comparison of sequence diversity across Clic and Flic repertoires despite their use of different scaffolds, a single functionally rearranged V(D)J scaffold versus multiple combinatorially assembled V(D)J scaffolds, respectively. The rich epitope diversity of both OmniClicTM and OmniFlic® yielded multiple candidates for functional NK activators, as determined in an antibody-dependent cellular cytotoxicity assay, demonstrating their value as building blocks in constructing optimized immune engagers.

  • Open Access

    Molecular basis for plasma membrane recruitment of PI4KA by EFR3

    by Sushant Suresh, Alexandria L. Shaw, Joshua G. Pemberton, Mackenzie K. Scott, Noah J. Harris, Matthew A. H. Parson, Meredith L. Jenkins, Pooja Rohilla, Alejandro Alvarez-Prats, Tamas Balla, et al.

    The lipid kinase phosphatidylinositol 4 kinase III α (PI4KIIIα/PI4KA) is a master regulator of the lipid composition and asymmetry of the plasma membrane. PI4KA exists primarily in a heterotrimeric complex with its regulatory proteins TTC7 and FAM126. Fundamental to PI4KA activity is its targeted recruitment to the plasma membrane by the lipidated proteins EFR3A and EFR3B. Here, we report a cryogenic electron microscopy structure of the C terminus of EFR3A bound to the PI4KA-TTC7B-FAM126A complex, with extensive validation using both hydrogen deuterium exchange mass spectrometry, and mutational analysis. The EFR3A C terminus undergoes a disorder-order transition upon binding to the PI4KA complex, with an unexpected direct interaction with both TTC7B and FAM126A. Complex disrupting mutations in TTC7B, FAM126A, and EFR3 decrease PI4KA recruitment to the plasma membrane. Multiple posttranslational modifications and disease linked mutations map to this site, providing insight into how PI4KA membrane recruitment can be regulated and disrupted in human disease.


  • Open Access

    Structure of Calcineurin bound to PI4KA reveals dual interface in both PI4KA and FAM126A

    by Alexandria L Shaw, Sushant Suresh, Matthew Ah Parson, Noah J Harris, Meredith L Jenkins, Calvin K Yip, John E Burke

    Phosphatidylinositol 4-kinase alpha (PI4KA) maintains the PI4P and phosphatidylserine pools of the plasma membrane. A key regulator of PI4KA is its association into a complex with TTC7 and FAM126 proteins. This complex can be regulated by the CNAβ1 isoform of the phosphatase Calcineurin. We previously identified that CNAβ1 directly binds to FAM126A. Here, we report a cryo-EM structure of a truncated PI4KA complex bound to Calcineurin, revealing a direct Calcineurin interaction with PI4KA. Additional HDX-MS and computational analysis show that Calcineurin forms a complex with an evolutionarily conserved IKISVT sequence in PI4KA’s horn domain. We also characterised conserved LTLT and PSISIT Calcineurin binding sequences in the C-terminus of FAM126A. These sites are in close proximity to phosphorylation sites in the PI4KA complex, suggesting key roles of Calcineurin-regulated phosphosites in PI4KA regulation. This work reveals novel insight into how Calcineurin can regulate PI4KA activity.